亞培公司自願撤回諾美婷在美國,加拿大和澳大利亞
紐約 - 2010年10月8號 - 亞培將自願撤回諾美婷(Meridia,Reductil)由美國市場的請求,美國食品和藥物管理局,加拿大的市場在加拿大衛生部的要求,從澳大利亞的市場在請求的治療物品管理局。
諾美婷在歐洲市場已經暫停了歐洲藥品局。
這些要求主要基於結果的諾美婷心血管Outome審判(童軍),這表明風險增加嚴重心血管事件相關的諾美婷使用與患者有潛在心血管問題。
其目的的上市後研究之間的聯繫,以確定長期使用諾美婷及風險患者心血管事件與預先存在的心血管疾病,或誰是高危險群心臟有關的不良事件。 超重和肥胖近萬例,年齡 55歲以上的人參加了審訊長達 6年。
最終結果的分析,研究證實以來有一個上升的風險主要心臟事件,如心肌梗死和腦卒中的肥胖和超重患者服用諾美婷。 此外,增加的風險並不顯著差異在不同的患者亞群的研究。
當諾美婷是第一個授權銷售 2000年12月,這是不推薦使用患者患有心血管疾病。
然而,儘管以前的風險緩解措施,但仍然是關注的風險增加心臟相關的不良事件,特別是因為人們對心血管疾病的危險可能沒有症狀。
鑑於這種關切,以及積累的科學證據的安全性和有效性西布曲明,已經確定的益處不再大於風險,這種藥物。
患者應該停止使用諾美婷和請教醫生的替代品。
Abbott Voluntarily Withdraws Sibutramine in the United States, Canada, and Australia
NEW YORK -- October 8, 2010 -- Abbott will voluntarily withdraw sibutramine (Meridia; Reductil) from the United States market at the request of the US Food and Drug Administration, from Canada's Market at the request of Health Canada, and from Australia's market at the request of the Therapeutic Goods Administration.
Marketing of sibutramine in Europe has already been suspended by the European Medicines Agency.
The requests are based primarily on the results of the Sibutramine Cardiovascular Outome Trial (SCOUT), which suggest an increased risk of serious cardiovascular events associated with sibutramine use in patients with underlying cardiovascular problems.
The purpose of the post-marketing study was to determine a link between long-term sibutramine use and the risk of cardiovascular events in patients with pre-existing cardiovascular disease, or who were at risk of heart-related adverse events. Nearly 10,000 overweight and obese patients aged 55 years and older were enrolled in the trial for up to 6 years.
Analysis of the final results of the study have since confirmed there is an increased in risk of major cardiac events such as myocardial infarction and stroke in obese and overweight patients taking sibutramine. Furthermore, the increased risk is not significantly different across various patient subgroups in the study.
When sibutramine was first authorised for sale in December 2000, it was not recommended for use in patients with existing cardiovascular disease.
However, despite previous risk mitigation measures, there continues to be concern of an increased risk of heart-related adverse events, particularly because people at risk of cardiovascular disease may not have symptoms.
In light of this concern, and the accumulating scientific evidence on the safety and efficacy of sibutramine, it has been determined that the benefits no longer outweigh the risks for this drug.
Patients should discontinue use of sibutramine and consult their physician for alternatives.
SOURCE: Abbott, Health Canada, and the Australian Department of Therapeutic Goods Administration
|